Juvaris BioTherapeutics Announces Cooperative Research And Development Agreement With The Centers For Disease Control And Prevention

Juvaris BioTherapeutics, Inc. announced that The Centers for Disease Control and Prevention and Juvaris BioTherapeutics, Inc. have entered into a Cooperative Research and Development Agreement (CRADA) for the evaluation of a JVRS-100 adjuvanted H5N1 pandemic influenza vaccine. The ability of JVRS-100 to aid in the induction of a protective antibody response to the H5N1 vaccine at low doses of vaccine will be confirmed.

More: continued here

Filed under: Bird Flu on January 17th, 2008